A Phase 1 Trial of Targeted Immunotherapy with Daratumumab Following Myeloablative Total Body Irradiation (TBI)-Based Conditioning and Allogeneic Hematopoietic Cell Transplantation (HCT) in Children, Adolescents and Young Adults with High-Risk T-Cell Acut

Allyson Flower, Troy C. Quigg, David T. Teachey, Megan Lim, Yanling Liao, Lauren Harrison, Erin Morris, Amir Steinberg, Stephan Voss, Rodney R Miles, Xiaokui Mo, Joseph Stanek, Adam Olshen, Michelle Hermiston, Alix E. Seif, Mitchell S. Cairo. A Phase 1 Trial of Targeted Immunotherapy with Daratumumab Following Myeloablative Total Body Irradiation (TBI)-Based Conditioning and Allogeneic Hematopoietic Cell Transplantation (HCT) in Children, Adolescents and Young Adults with High-Risk T-Cell Acute Lymphoblastic Leukemia and Lymphoma (T-ALL/T-LLy) (ALLO-T-DART): A Ptctc Facilitated Study. Transplantation and Cellular Therapy. 2025 Feb 1; 31(2):s433-s434.